



Cell Line Development

Powered by Selexis®

Made to Flex. Built to Scale. Proven to Deliver.

Slow, unpredictable cell line development can cost you precious time, especially in early development, when timelines are tight and the pressure to deliver is high.

Every molecule has a unique path. We help you build the right one from the start.

Whether you're developing standard mAbs, advanced multispecific antibodies, or conjugate molecules, KBI Biopharma's modular cell line development (CLD), powered by the industry-leading Selexis® platform, delivers stable, scalable, and submission-ready results at the speed your program demands.

Your Protein, Our Cells

You know your protein. We know how to express it.

Our modular CLD, powered by the Selexis® SUREtechnology suite, delivers an industry-leading platform with flexibility to meet program needs, without compromising on cutting-edge innovation.

Expertise That Delivers

With 11 approved biologics and a proven track record in complex molecule expression, the award-winning Selexis® SUREtechnology™ platform sets the industry standard for high-performance CLD.

At KBI Biopharma, we bring together this platform and our expert team under one CDMO to streamline your journey from sequence to clinic and beyond. From early clone selection through cGMP tech transfer and commercial manufacturing, our fully integrated CLD, process development, analytical, and cGMP teams collaborate seamlessly to minimize rework, mitigate risk, and accelerate your path to clinic.

Selexis® CHO-M™

The Standard Cell Line for Protein Expression

Proven cell line that supported 10+ marketed biologics

Selexis® TranspoEase™

Next-Generation in Expression Systems

For high-titer and improved stability

Selexis® CHOKOL8™

FUT8 KO Cell Line for Enhanced ADCC

Proven cell line technology for afucosylated antibodies


Selexis® Transient™

Rapid Early-Stage Selexis® CHO-M™ Expression Feasibility Platform


For proof of concept with predictable performance

See the Selexis® TranspoEase™ difference :

Efficiency across diverse biologics



Consistent quality across generations




Titer loss over 60 generations

91% of Stable Cell Line

- SuperStable: G0/G60 < 10%
- Stable: 10% < G0/G60 < 30%
- Unstable: G0/G60 > 30%

A Platform Built to Scale

From codon optimization and proprietary vectors to semi-targeted transposase integration and high-throughput clone selection, every step is engineered to minimize variability, and drive confident decisions. The outcome? A stable, high-expressing research cell bank, IND-ready and seamlessly transferable to KBI Biopharma's integrated cGMP manufacturing network.



Let's Build the Right Path for Your Molecule Together



Whether you're starting out or scaling up, our team is ready to design the optimal cell line strategy for your molecule. Contact us to explore special pricing crafted to accelerate your start, mitigate risk, and ensure confidence on your journey to clinic.

Scan to schedule a consultation with our experts and explore the platform in more detail.